TW307769B - - Google Patents

Download PDF

Info

Publication number
TW307769B
TW307769B TW082105942A TW82105942A TW307769B TW 307769 B TW307769 B TW 307769B TW 082105942 A TW082105942 A TW 082105942A TW 82105942 A TW82105942 A TW 82105942A TW 307769 B TW307769 B TW 307769B
Authority
TW
Taiwan
Prior art keywords
hydrochloride
patent application
water
crystalline hydrate
hydrate
Prior art date
Application number
TW082105942A
Other languages
English (en)
Chinese (zh)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of TW307769B publication Critical patent/TW307769B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW082105942A 1992-07-31 1993-07-26 TW307769B (online.php)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
TW307769B true TW307769B (online.php) 1997-06-11

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082105942A TW307769B (online.php) 1992-07-31 1993-07-26

Country Status (23)

Country Link
US (1) US5407929A (online.php)
EP (1) EP0581552B1 (online.php)
KR (1) KR100245938B1 (online.php)
CN (1) CN1037683C (online.php)
AT (1) ATE165360T1 (online.php)
AU (1) AU657866B2 (online.php)
BR (1) BR9303235A (online.php)
CA (1) CA2101502A1 (online.php)
DE (1) DE69318077T2 (online.php)
ES (1) ES2115725T3 (online.php)
FI (1) FI933391L (online.php)
GR (1) GR3026699T3 (online.php)
HU (1) HU219637B (online.php)
IL (1) IL106516A (online.php)
MX (1) MX9304611A (online.php)
NO (1) NO303734B1 (online.php)
NZ (1) NZ248285A (online.php)
PH (1) PH30109A (online.php)
PL (2) PL172835B1 (online.php)
RU (1) RU2118959C1 (online.php)
TW (1) TW307769B (online.php)
UA (1) UA37181C2 (online.php)
ZA (1) ZA935529B (online.php)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05643B1 (et) * 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CN101219992B (zh) 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
JP5230934B2 (ja) 2003-03-27 2013-07-10 バジリア ファルマスーチカ アーゲー 結晶形態のセファロスポリン
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) * 2008-08-15 2019-12-18 Boehringer Ingelheim Int Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
PH30109A (en) 1996-12-27
HUT68602A (en) 1995-06-28
MX9304611A (es) 1994-02-28
CN1037683C (zh) 1998-03-11
UA37181C2 (uk) 2001-05-15
IL106516A0 (en) 1993-11-15
GR3026699T3 (en) 1998-07-31
FI933391A0 (fi) 1993-07-29
NO303734B1 (no) 1998-08-24
AU4422793A (en) 1994-02-03
ATE165360T1 (de) 1998-05-15
NZ248285A (en) 1994-07-26
HU9302194D0 (en) 1993-10-28
FI933391A7 (fi) 1994-02-01
AU657866B2 (en) 1995-03-23
ES2115725T3 (es) 1998-07-01
IL106516A (en) 1998-06-15
EP0581552A3 (en) 1994-06-01
BR9303235A (pt) 1994-03-01
ZA935529B (en) 1994-02-24
NO932745D0 (no) 1993-07-30
DE69318077T2 (de) 1998-10-29
RU2118959C1 (ru) 1998-09-20
EP0581552B1 (en) 1998-04-22
FI933391L (fi) 1994-02-01
CA2101502A1 (en) 1994-02-01
US5407929A (en) 1995-04-18
PL172830B1 (pl) 1997-12-31
KR940005636A (ko) 1994-03-22
NO932745L (no) 1994-02-01
CN1089948A (zh) 1994-07-27
PL172835B1 (pl) 1997-12-31
DE69318077D1 (de) 1998-05-28
KR100245938B1 (ko) 2000-04-01
EP0581552A2 (en) 1994-02-02
PL299870A1 (en) 1994-02-07
HU219637B (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
US5407929A (en) Triazolylthiomethylthio cephalosporin hydrochhloride, its crystalline hydrate and the production of the same
JPH0255437B2 (online.php)
NL192266C (nl) Werkwijze voor het bereiden van een kristallijn cefepime-dihydrochloride alsmede het kristallijne dihydrochloride en mengsels die het bevatten.
JP2009143957A (ja) アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
ES2390611T3 (es) Agente de erradicación de Helicobacter pylori que tiene actividad inhibidora sobre la secreción de ácido gástrico
TWI293631B (online.php)
DK163514B (da) Fremgangsmaade til fremstilling af en krystallinsk form af natriumsaltet af et oximderivat af 7-aminothiazolylacetamidocephalosporansyre
FR2466469A1 (fr) Bischlorhydrate de cephalosporine, son procede de preparation et ses applications, notamment en therapeutique
JPS62294615A (ja) 抗菌剤
KR100332280B1 (ko) 항헬리코박터 필로리제
JP2575590B2 (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
JPH0741484A (ja) セフェム化合物及び抗菌剤
US10717729B2 (en) Thiamine-organic acid salt
CA2082472A1 (en) Crystalline form of a cephalosporin antibiotic
FR2884822A1 (fr) Derives de triazines, leur preparation et leur application en therapeutique
HU204271B (en) Process for producing cristalline 1-carba-dethia-cepheme-solvates
SU973024A3 (ru) Способ получени аддитивных солей пивалоилоксиметилового эфира 7 @ -[2-(2-аминотиазол-4-ил) ацетамидо]-3-[1-(2-диметиламиноэтил)-1н-тетразол-5-илтиометил]-3-цефем-4-карбоновой кислоты с сол ной,винной или лимонной кислотой
FR2952M (online.php)
RU2785195C1 (ru) Способ получения полиморфной формы 4-(3-этокси-4-гидроксибензил)-N-(2,4-дифторфенил)-5-оксо-5,6-дигидро-4H-1,3,4-тиадиазин-2-карбоксамида
US3682953A (en) Substituted 5-nitrofuryl-pyrazoles
US20110118462A1 (en) N-heterocyclic substituent-containing antibiotic, preparation and use thereof
JPH04234880A (ja) β−ラクタム抗生物質の結晶性塩酸塩
US3835165A (en) Nitrofuryl-alpha-halo-hydrazones
DE69312322T2 (de) Cephem verbindungen mit antimicrobizide eigenschaften
JPS58154589A (ja) セフアロスポリン誘導体